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Metagenomic analysis of gut 
microbiota in non‑treated plaque 
psoriasis patients stratified 
by disease severity: development 
of a new psoriasis‑Microbiome 
index
ignacio Dei‑cas1,2,3, Florencia Giliberto4,5, Leonela Luce4,5, Hernán Dopazo6 & 
Alberto penas‑Steinhardt7,8*
psoriasis is an immune‑mediated skin disorder. imbalance of gut microbial populations has been 
implicated in many diseases. We aimed to investigate whether there were differences in gut 
microbiota in psoriasis patients vs non-psoriasis controls and between psoriasis severity groups. 55 
psoriasis patients and 27 controls were included. V3–V4 regions of the 16S rRNA gene of fecal samples 
were analyzed using Illumina MiSeq. Bioinformatic analysis was performed. We found changes 
in gut microbiome composition depending on their psoriasis status as determined by weighted 
unifrac (p < 0.05), in particular an increase in Firmicutes and depletion of Bacteroidetes in psoriasis 
patients. Additionally, the Faecalibacterium and Blautia genus were higher in psoriasis patients while 
Bacteroides and Paraprevotella in non-psoriasis controls (p < 0.05, LDA score > 2). Moderate-to-severe 
psoriasis patients had lower biodiversity than mild psoriatic patients (p = 0.049). No differences for 
beta-diversity were found. We developed a Psoriasis-Microbiota Index (PMI), which discriminated 
among psoriasis patients and controls with sensitivity: 0.78 and specificity: 0.79. Furthermore, we 
performed a meta‑analysis with published data to validate this index. We demonstrated gut dysbiosis 
in psoriasis patients, suggesting a role in psoriasis pathophysiology. Furthermore, we developed 
a PMI with the potential to discriminate between psoriasis patients and controls across different 
populations, which could be used as a biomarker in the clinical practice.
Psoriasis is a chronic, immune-mediated inflammatory skin disease. It ranges in severity from a few scattered red, 
scaly plaques to involvement of almost the entire body  surface1. Psoriasis is estimated to affect about 2–4% of the 
population in western countries, causes considerable psychosocial disability and has a major impact on patients’ 
quality of  life2,3. Skin lesions are characterized by angiogenesis, an inflammatory reaction with recruitment of T 
cells into the skin, hyperproliferation of keratinocytes and altered epidermal  differentiation4. Genetic and envi-
ronmental factors are implicated in psoriasis, although, the exact etiology of the disease is not fully  understood5,6.
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The Human Microbiome Project (HMP) was initiated to fill a gap between our current understanding derived 
from Human Genome Project and actual physiological phenomenon. The HMP created a new view of ourselves 
as ‘super-organisms’ consisting of a human host and thousands of microbial  symbionts7.
Imbalance of gut microbial populations or dysbiosis has important functional consequences and has been 
implicated in many digestive diseases, diabetes, obesity, metabolic syndrome, psoriatic arthritis, celiac disease, 
psychiatric disorders and  others8–13.
There is a well-known relationship between psoriasis and other inflammatory diseases (obesity, inflammatory 
bowel disease, psoriatic arthritis, etc.)14. More importantly, bowel mucosa of active psoriasis patients without 
bowel symptoms show microscopic lesions, even when mucosa appeared macroscopically normal, with immune 
cellular infiltrates capable of producing pro-inflammatory  cytokines15. Bacterial DNA translocation from the 
intestinal lumen has been described in patients with psoriasis suggesting that the gut microbiome may potentially 
act in skin  diseases16,17,18.
Recent investigations point to the IL-23/Th17 axis as playing a major role in psoriasis  pathogenesis19. The 
adhesion of specific members of gut microbiome to intestinal epithelial cells is found to be essential for the induc-
tion of Th17  cells20–22. Mice exposed to antibiotics showed inhibition of psoriasis induction by a dysregulation 
of gut and skin  microbiota23–25.
There have been only limited studies of microbiota in psoriasis patients using molecular methods, which 
showed contradicting results regarding the most abundant taxa in the disease. These studies involved relatively 
small numbers of subjects, skin and gut microbiota and unmatched study  designs6,17,26–38. Furthermore, none of 
existing reports evaluated changes in the gut microbiota among disease severity groups.
In the present study, we aimed to investigate whether the microbiota composition of non-treated chronic 
plaque psoriasis patients, as a group and divided according to disease severity, differs from non-psoriasis controls. 
We used strict inclusion and exclusion criteria. We included only patients with chronic plaque psoriasis and 
excluded patients with PsA and IBD (psoriasis comorbidities that are related to changes in the gut microbiota) 
and those patients under active systemic treatment, since there is evidence that methotrexate and biologic drugs 
induce compositional changes in the gut  microbiota39–41. In addition, controls should not have family history of 
psoriasis in first degree relatives as genetics could also shape the gut  microbiota42. Granted that there is abundant 
evidence that overweight or obese subjects have changes in their gut microbiota in relation to controls and that 
obesity and metabolic syndrome are comorbidities of psoriasis, we matched patients by sex, age and  BMI43,44. 
Furthermore, we designed a Psoriasis-Microbiota Index (PMI) to discriminate patients against controls and 
performed a meta-analysis with previously published data to validate this index.
Results
Background of study cohort. This study included 55 untreated chronic plaque psoriasis patients and 27 
unrelated non-psoriasis controls. The background of patients and controls are shown in Table 1. The patient 
group included 28 with mild disease and 27 with moderate-to-severe psoriasis. Table 2 represents the demo-
graphic data between mild and moderate-to-severe psoriasis groups, in which patients were comparable except 
for disease duration (longer in moderate-to-severe patients) and time since last relapse (longer for mild psoria-
sis).
Table 1.  Characteristics of the sample.
Psoriasis patients Non-psoriasis controls p
n: 55 n: 27
Age (years), mean ± SD 44.8 (16.9) 48.7 (18.8) NS
Female (%) 49.1 57.7 NS
Male (%) 50.9 42.3 NS
Age of Psoriasis symptom onset (years), mean ± SD 30.5 (17.5) NA
Type 1 Psoriasis (%) 69.1 NA
Last outbreak of Psoriasis symptoms (months), mean ± SD 4.2 (2.0) NA
Duration of Psoriasis (years), mean ± SD 14.3 (12.0) NA
Moderate-to-severe Psoriasis (%) 49.1 NA
Hypertension (%) 29.1 NA
Diabetes (%) 16.4 NA
Weight, mean ± SD 81.8 (19.9) 75 (15.1) NS
Heigh, mean ± SD 1.66 (0.1) 1.63 (0.1) NS
BMI, mean ± SD 29.6 (5.5) 28.1 (5.2) NS
Metabolic syndrome (%) 21.8 NA
Overweight (%) 29.1 42.3 NS
Obesity (%) 45.5 30.7 NS
PASI, mean ± SD 9.9 (7.2) NA
BSA, mean ± SD 14.5 (18.5) NA
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psoriasis vs non‑psoriasis controls. Sequence analysis and comparison of microbial communities. The 
hypervariable region V3-V4 of bacterial 16S gene was sequenced using MiSeq-Illumina system, obtaining 
152,939.46 ± 18,320.34 sequences per sample. Rarefaction plots reached an asymptotic state, indicating that the 
sequence depth was sufficient to represent the bacterial community richness and diversity (data not shown). 
Therefore, when we compared species richness (Chao1 index), there were no significant differences between 
psoriasis patients and controls. For beta-diversity as determined by Unifrac, we found significant differences be-
tween both groups, p = 0.034 for weighted UniFrac (Fig. 1) but not for unweighted UniFrac p = 0.255 (ADONIS).
Psoriasis patients differ from controls in the observed community structure. The dominant phyla in psoriasis 
patients were Bacteroidetes 47.1%, Firmicutes 44.6%, Proteobacteria 5.4%, Actinobacteria 0.8% and Fusobacteria 
0.7%, while the principal phyla found in controls were Bacteroidetes 59.9%, Firmicutes 33.0%, Proteobacteria 
4.2%, Verrucomicrobia 1.4% and Actinobacteria 0.8% (Fig. 2).
Phyla-level differences were detected between the two groups (control vs Psoriasis patients) including differ-
ences in Bacteroidetes and Firmicutes, with a Firmicutes to Bacteroidetes ratio of 0.63 ± 0.32 in non-psoriasis con-
trols and 1.29 ± 0.81 in psoriasis patients (p = 0.0002). LefSe analysis revealed that these differences were mainly 
driven by changes in the Bacteroides and Paraprevotella genus which were more abundant in non-psoriasis con-
trols while Faecalibacterium and Blautia in psoriasis patients (logarithmic LDA scores threshold was 2.0) (Fig. 3). 
We did not observe significant differences in gut microbiota associated with changes in age, weight and BMI.
Mild vs moderate‑to‑severe psoriasis. Species richness in moderate-to-severe psoriasis patients was 
lower comparing with mild psoriasis patients (p = 0.049). Comparing the principal phyla detected, we did not 
find differences between both psoriasis groups (Supplementary Fig. S1).
We did not find differences in beta-diversity in mild vs moderate-to-severe psoriasis patients Supplementary 
Fig. S2. We did not observe significant differences for age, gender, age at psoriasis onset, years with psoriasis, 
hypertension, diabetes, weight, BMI, PASI and BSA. Only significant differences were found for metabolic syn-
drome (p = 0.002) in unweighted analysis.
psoriasis‑Microbial index. Considering the results of relative abundance of different taxa, we generated 
the PMI to discriminate between psoriasis and non-psoriasis controls (Fig. 4a). We evaluated its applicability by 
ROC analysis. The Area Under the Curve (AUC) for the classification of Psoriasis (training dataset) was 0.797 
(Fig. 4b), determining an optimal cut-off value of PMI = − 1.00 (sensitivity = 0.78 and specificity = 0.79) (Fig. 4c). 
When we applied the PMI according to psoriasis severity, the AUC was 0.849 and 0.743 for mild and moderate-
to-severe psoriasis respectively.
Meta‑analysis. We validated this PMI using datasets from previously reported literature on PubMed. We 
identified 7 related 16S  datasets6,17,26,27,29,34,35. Only the study of Hidalgo-Cantabrana et al.34 fulfilled the inclusion 
criteria.
When we applied the PMI to the downloaded sequence data from Hidalgo-Cantabrana et al.(test dataset)34 
(Fig. 4a), the AUC was 0.953, Sensitivity = 0.89 and Specificity = 0.90, using cut-off value obtained with our 
dataset (PMI = − 1.00);(Fig. 4b). Sensitivity vs Specificity curves of both datasets were plotted in Fig. 4c showing 
Table 2.  Demographic data in mild and moderate-to-severe psoriasis patients.
Mild psoriasis patients Moderate-to-severe psoriasis patients p
n: 28 n: 27
Age, mean ± SD 41 ± 14.2 48.6 ± 18.9 NS
Female n: 27 (%) 42.9 55.6 NS
Male n: 28 (%) 57.1 44.4 NS
Age of Psoriasis symptom onset (years), mean ± SD 31 ± 15 29.9 ± 19.8 NS
Type 1 Psoriasis n: 38 (%) 47.4 52.6 NS
Last outbreak of Psoriasis symptoms (months), mean ± SD 4.7 ± 2.1 3.6 ± 1.7 0.04
Years with Psoriasis, mean ± SD 9.9 ± 8.7 18.6 ± 13.4 0.008
Hypertension n: 16 (%) 28.6 29.6 NS
Diabetes n: 9 (%) 17.9 14.9 NS
Weight, mean ± SD 85 ± 19.5 79.1 ± 20.2 NS
Heigh, mean ± SD 1.68 ± 0.1 1.64 ± 0.1 NS
BMI, mean ± SD 29.9 ± 5.8 29.5 ± 5.3 NS
Metabolic syndrome n: 12 (%) 21.4 22.2 NS
Overweight n: 16 (%) 28.6 29.6 NS
Obesity n: 25 (%) 46.4 44.4 NS
PASI, mean ± SD 3.7 ± 1.1 16.3 ± 4.8 0.000001
BSA, mean ± SD 2 ± 1.2 27.5 ± 19.2 0.000001
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Figure 1.  PCoA of beta-diversity values (Weighted Unifrac distances). Comparison of the gut microbiota from 
psoriasis patients and non-psoriasis controls. Ellipses show 95% confidence intervals.
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concordant results, indicating that PMI would be a powerful tool capable of discriminating between patients 
with psoriasis and controls from different populations.
Discussion
Intestinal dysbiosis is a possible actor in chronic inflammation, even in distant tissue sites, such as the skin. Imbal-
ance in gut microbiota induces epithelial changes resulting in increased intestinal inflammation and altered gut 
permeability, which in susceptible individuals may trigger the development of different chronic disease states 
Figure 3.  Plot from LEfSe analysis indicating enriched bacterial genus associated either with psoriasis patients 
(red) or non-psoriasis controls (blue). The length of the bar column represents the LDA score (a). Cladogram 
plotted from LEfSe analysis showing the differences in relative abundance of taxa at five levels between psoriasis 
patients vs non-psoriasis controls. (P < .05; LDA score 2) (b).
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such as IBD, obesity, diabetes, multiple sclerosis, atopic dermatitis and cancer, among  others45–50. However, until 
now, only a few studies have addressed this question in  psoriasis6,17,26,27,29,34–36,33.
Our work demonstrates that there are differences in gut microbiota between psoriasis patients and non-
psoriasis controls. We evaluated 55 untreated chronic plaque psoriasis patients (27 with moderate-to-severe 
psoriasis and 28 with mild disease), being according to our knowledge the study with the highest number of 
psoriasis patients and the first which evaluates changes in gut microbiota according to psoriasis severity based 
on well-defined strict criteria. We made a comparison of our study design with all the available publications on 
gut microbiota and psoriasis up to March 31, 2020 (Table 3).
Alpha-diversity has been observed to be decreased in a dysbiotic  gut51. A lower microbial diversity has been 
found in some psoriasis  studies6,29,34 but not by other  investigators17,26,27,35. Our study does not show a lower 
alpha-diversity.
We found that Bacteroidetes and Firmicutes were the most prevalent phyla in patients and controls. How-
ever, there were significant differences between both phyla in psoriasis patients. The Firmicutes to Bacteroidetes 
ratio was 1.29 ± 0.81 in psoriasis patients and 0.63 ± 0.32 in non-psoriasis controls. In line with our results, other 
investigations showed a high Firmicutes:Bacteroidetes  ratio6,27,29,34,35.
Short Chain Fatty Acid (SCFA) like acetate, propionate and butyrate, are known to regulate not only gut 
specific but also distant inflammatory responses through the induction of immune  cells52. An increase in 
Firmicutes:Bacteroidetes ratio has been implicated in a higher acetate and lower butyrate production. Butyrate 
is the preferred fuel for the colonic epithelial cells and the major regulator of cell proliferation and differentiation, 
and has important anti-inflammatory, antioxidant and anti-carcinogenic  functions53. Low levels of butyrate may 
affect the integrity of the mucous layer compromising the gut epithelial barrier and enhance chronic colonic 
and systemic  inflammation54.
Beta-diversity showed that genus Faecalibacterium and Blautia (both belong to the phylum Firmicutes, class 
Clostridia and order Clostridiales) were the most relevant genus in psoriasis patients that discriminated against 
non-psoriasis controls. Faecalibacterium prausnitzii (F. prausnitzii) can regulate T helper 17 cell (Th17)/regula-
tory T cell (Treg) differentiation and has been consistently reported as one of the main butyrate producers found 
Figure 4.  PMI distinguishes non psoriasis controls from psoriasis patients. Violin plot showing PMI in control 
and psoriasis fecal samples (a). Performance of cross-city prediction using each city-specific AD diagnosis 
model, as assessed via the area under the ROC curve (AUROC). The ROC curve of tenfold cross-validation was 
marked as blue lines and the ROC curve of the prediction as red lines. Performance of PMI, assessed via the area 
under the ROC curve (AUROC) (b). Sensitivity and specificity vs. PMI (Cutoff) plot in both populations (c).
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in the  intestine53,55. The role of F. prausnitzii in maintaining immune and physiological functions promoted this 
bacterium as a next generation  probiotic56.
In psoriasis, a decrease in relative abundance of F. Prausnitzii has been reported in some  studies30,34, but not 
by other  investigators17,27,35. In our study the genus Faecalibacterium showed higher values in psoriasis patients. 
Lopez-Siles et al. determined that F. prausnitzii includes two phylogroups and recent studies suggest that other 
Faecalibacterium genus and species could not be ruled  out53,57,58. The relative abundance, as well as which phylum 
and species of Faecalibacterium population are disbalanced in different diseases, makes it difficult to establish 
the use of a single bacteria as a general biomarker for all diseases. The use of F. prausnitzii as a gold standard of 
a healthy gut microbiota is  limited53.
The genus Blautia includes obligate anaerobic intestinal commensal bacteria that belong to the family Lach-
nospiraceae and includes more than 100 different  species59,60. Blautia are important members of the healthy 
human gut  microbiota61. Jenq et al. found a lower mortality due to a graft versus-host disease after allogeneic 
blood/marrow transplantation among patients with high abundance of Blautia and Bajaj et al.found that Blautia 
was one of the bacteria associated with improved outcomes in patients with liver  cirrhosis62,63. Genus Blautia 
has been also related to cancer. Chen et al.reported a detrimental association between lower concentrations of 
Blautia in the gut and colorectal  cancer64. On the contrary, Luu et al. found that higher levels of Blautia were 
associated with poor prognosis in patients with early-stage breast  cancer65. Considering the limited data avail-
able on Blautia and the huge number of species reported, we can not explain the reasons why genus Blautia was 
increased in our work. Additional data are required to determine their true role in human diseases.
The fact that most relevant genus in psoriasis patients that discriminated against non-psoriasis controls were 
Faecalibacterium and Blautia, taxa producing high levels of butyrate, contradicts the traditional association of 
butyrate producers observed in diseases such as  IBD66,67. Therefore, results highlight the need for additional 
research given the observational nature and limits of 16S used in this study.
In our control group, the predominant genus were Bacteroides and Paraprevotella. These bacteria differ only in 
family (Bacteroideaceae for Bacteroides and Prevotellaceae for Paraprevotella)68,69. Increasing evidence proposes 
that Bacteroides harness complex recalcitrant  glycans70. SCFAs are the major metabolic products of anaerobic 
fermentation of glycans by gut bacteria and have been shown to impact on the host  physiology71. The beneficial 
effect of Bacteroides is consistent with our findings, where this genus was increased in controls and depleted in 
psoriasis patients.
There is evidence that age, diet, geographical location, genetics and antibiotics, among other factors, influence 
gut  microbiota72,73. We selected unrelated controls matched by sex, age and BMI to moderate-to-severe psoriasis 
patients, living in the same area and with a similar diet in order to reduce those confounding factors. We did not 
find differences in beta-diversity according to personal features, so we postulate that changes in gut microbiota 
would then be dependent on psoriasis and not on other covariates.
We found that patients with moderate-to-severe psoriasis had a lower diversity (species richness) than patients 
with mild disease, although this difference was subtle. Only Huang et al.also studied whether the composition 
of the intestinal microbiota differed depending on the severity of the disease and they found that the genus 
Bacteroides was increased in patients with psoriasis and that it was characteristic of the subgroup with severe 
 disease6. In our study, the genus Bacteroides was found to be diminished in patients with psoriasis but no dif-
ferences were found between mild and moderate-to-severe psoriasis patients. For example, these distinctions 
could be due to different inclusion criteria.
Table 3.  Study design of the available publications included in the meta-analysis (up to March 31, 2020).
Our study Codoñer et al.20 Tan et al.29
Hidalgo-
Cantabrana et al.37 Chen et al.30 Huang et al.6 Scher et al.32 Shapiro et al.38
Publication year 2018 2018 2019 2018 2018 2015 2019
Population Caucasian/Argen-tine Caucasian/Spain Asian/China Caucasian/Spain Asian/China Asian/China Caucasian/US Caucasian/Israel
Psoriasis patients (n) 55 52 14 19 35 32 15 Ps / 16 PsA 24
Non-Psoriasis 
controls (n) 27 300 (from HMP) 14 20 27 64 17 22
Plaque psoriasis 
exclusive yes yes yes yes yes no NA NA
Matchead by Age, sex & BMI No No Age Age, sex & BMI No Age & sex Age, sex & comor-bidities
Active systemic 
treatment No No NA No Yes Yes No Yes
Stratified by severity Yes No No No NA Yes No No
Concomitant PsA no NA NA NA yes no yes NA
16S region analyzed V3–V4 V3–V4 V4 V2–V3 V3–V4 V4–V5 V1–V2 V4
Platform Illumina Illumina Illumina Ion Chef Illumina Illumina Illumina Illumina
Average reads 152,939  ~ 85,000  ~ 30,000 233,113  ~ 85,000 NA NA  ~ 50,000
Raw data available at PRJNA574485
Avaiable upon 
request to the cor-
responding author
NA PRJNA517056 PRJNA379878 NA NA NA
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When we compared whether the microbiota of patients with mild psoriasis vs patients with moderate-to-
severe psoriasis was affected by age, sex, age at onset of the disease, years of illness and comorbidities such as 
hypertension or diabetes, we could not establish differences between both severity groups. These results could 
also explain that changes of the gut microbiota in psoriasis would be dependent on the presence of the disease 
and would not be affected by its severity.
Codoñer et al., Shapiro et al.and Hidalgo-Cantabrana et al.reported similar results to our study regarding 
the bacteria genus increased in psoriasis and  controls17,34,35. This concordance suggests that there is probably 
a core gut microbiota in psoriasis patients. Unfortunately, not all the studies met the inclusion criteria for the 
meta-analysis. Codoñer et al. did not use a control group from the same geographic location as they used pub-
licly available data from The Human Microbiome Project and the raw data from Shapiro et al.were not available. 
This serves as another example of the importance of unrestricted access to raw sequencing data, which has been 
already recognized by the scientific  community74. Despite variations among Hidalgo-Cantabrana et al.and our 
study, a psoriasis model can be applied across populations from different geographical locations. The proposed 
PMI proved to be able to discriminate between psoriasis and controls across cities and continents with an optimal 
cut-off value of PMI = − 1.00.
Given that general dermatologists are able to make a diagnosis of psoriasis with a simple physical exam, 
the diagnostic applicability of the test will have to await further clinical experience. The PMI represents, a step 
forward as a combined practical, ready to use, clinical and research tool. The index will allow us to gain more 
knowledge on the microbial component of psoriasis and provide the possibility of increasing our understanding 
of the role played by the microbiome in the disease process. Moreover, as PMI was only tested in 2 cohorts of 
non-treated patients, we cannot exclude its role as a biomarker for evaluating treatment response. Further studies 
of metagenome shotgun sequencing at the species/strain levels might be useful for the update and improvement 
of the developed PMI.
In summary, our findings demonstrate variations in gut microbiota profiles between non-treated plaque 
psoriasis patients and non-psoriasis controls. This results suggest that it is likely that altered gut microbiota 
plays a pathophysiological role in psoriasis. However, whether modulation of gut microbiota could modify the 
course of the disease remains to be explored. This study is unique in being the first to propose a PMI with the 
ability to discriminate between psoriasis patients and age-sex-and BMI matched controls and between samples 
from communities of different continents. Further studies are needed to better interpret the role of the PMI as a 
potential biomarker test in psoriasis, and to test this index in larger and diverse populations to confirm its validity.
Methods
Study participants. This cross-sectional study recruited unrelated individuals, including consecutive 
chronic plaque psoriasis patients and non-psoriasis controls. Controls were matched to moderate-to-severe pso-
riasis patients according to sex, age (± 2 years) and Body Mass Index (BMI; ± 1). Participants were caucasian, 
above 18 years old and from the same geographical location. Samples were collected between October 2017 and 
April 2018.
Psoriasis patients were subdivided based on their severity in mild and moderate-to-severe psoriasis. Mild 
psoriasis was defined as actual Body Surface Area covered by psoriasis (BSA) < 10%, Psoriasis Area and Sever-
ity Index (PASI) < 10, Investigator Global Assessment (IGA) < 3 and absence of episodes of moderate-to-severe 
psoriasis in the past. Moderate-to-severe psoriasis was defined as BSA ≥ 10%, PASI ≥ 10 and IGA ≥ 3.
Two visits were conducted over a period of 4 weeks to take a detailed assessment of psoriasis, medical history, 
and a complete physical exam, including PASI, IGA and BSA involvement. Type 1 psoriasis was defined if the 
symptoms began on or before age 40 years; a BMI ≥ 25 was considered as excessive weight and BMI ≥ 30 as obesity.
Key exclusion criteria for psoriasis patients included concomitant diagnosis of psoriatic arthritis accord-
ing to CASPAR criteria, inflammatory bowel disease (IBD), current topical treatment, systemic treatment for 
psoriasis (including phototherapy) 3 months previous to sample collection, assuming that immunosuppression 
could modify gut microbiota.
The exclusion criteria for controls were the presence of other dermatosis, family history of psoriasis in first 
degree relatives, immunological disorders, hypertension, fatty liver disease, diabetes mellitus, malignancy, any 
other serious internal disease, smoking and alcohol abuse.
Exclusion criteria applied to all groups were: antibiotic therapy 3 months previous to sample collection, 
extreme diet, consumption of probiotics, positive HIV test or any gastrointestinal tract surgery leaving perma-
nent residua.
Sample collection and DnA extraction. All participants were apprised for the stool sampling collection 
method by receiving a standardized protocol for the collection of approximately 5 g of stool in a sterile bacterio-
static buffer  tube75. Participants were asked to collect samples 24 h before the second visit. DNA extraction was 
performed from 200 mg of feces using QIAamp-PowerFecal DNA-Kit.
comparison of microbial communities and sequence analysis. Hypervariable regions V3–V4 of 
the 16S rRNA gene were amplified with primers 337F/805R and sequenced in paired-end mode using a MiSeq 
sequencer  (IlluminaⓇ), warranting an average of 152,939 sequences per sample.
De-multiplexed reads were quality trimmed using Trimmomatic(V0.36)76. Sequences generated were 
analyzed using Quantitative Insights Into Microbial Ecology (QIIME) version 1.9.1 software  package77. For 
this purpose, the sequences obtained were compared with those from Greengenes 13_8  database78. Chimeric 
sequences were filtered using  VSEARCH79. Operative Taxonomic Units (OTUs) were assigned to each read with 
an open_reference OTU picking process. SortMeRNA (v2.1)80 was used for the reference OTU picking steps 
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(with sortmerna_coverage = 0.8) and sumaclust (v1.0.20)81 for the de novo OTU picking steps (with 10% of the 
failures subsampled). Low-confidence OTUs called by < 0.1% of the reads were removed using the script remove_
low_confidence_otus.py82. An average of 29,872.93 ± 6,452.75 mapping high-quality sequences were obtained, 
leading to 455.91 ± 126.99 unique OTUs per sample. For multiple comparisons, p-values were adjusted by Bonfer-
roni  correction83. To compare microbial communities in different sample groups, we used Unifrac  algorithm84. 
Differences on beta-diversity were assessed using ADONIS. In order to compare the relative abundance of the 
different taxa between groups, we performed Linear Discriminant Analysis (LDA) effect implemented in  LEfSe85 .
psoriasis‑Microbiome index development. PMI was defined as the logarithm of total abundance of 
organisms increased in psoriasis over total abundance of organisms decreased in psoriasis for all samples (at 
genus level) using the compute_taxonomy_ratio.py  script86. Then, we evaluated how these PMI performed for 
classification subjects by psoriasis status through Receiver Operating Characteristic (ROC) analysis (training 
dataset). ROC analysis was performed using ROCR package (RStudio version 1.1.453)87. Cut-off value was 
selected as the point where the sensitivity and specificity functions intersect each other, i.e. jointly maximizing 
the sensitivity and specificity of PMI.
Meta‑analysis. We performed a systematic literature search of PubMed databases up to March 31, 2020 
using the following terms: “Psoriasis” and “gut microbiota” or “gut microbiome”. The study inclusion criteria 
were: Case–control studies with publicly available raw 16S data and metadata, indicating case/control status for 
each sample. Studies including patients with other clinical forms different from plaque psoriasis and patients 
under systemic treatment (DMARDS and biologics) were excluded.
Data accession. Raw sequences of 16S rRNA gene reported in this article have been deposited in NCBI 
Short Read Archive (SRA) and are accessible under the accession number PRJNA574485.
ethical statement. This study received approval by the Ethics Committee of Hospital Español, Buenos 
Aires Argentina according to local regulations and Helsinki declaration. Written informed consent was obtained 
from all study participants.
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